Related Experiment Videos
Cabergoline treatment of risperidone-induced hyperprolactinemia: a pilot study
Roberto Cavallaro1, Federica Cocchi, Sara M Angelone
1Department of Neuropsychiatric Sciences, San Raffaele Scientific Institute Hospital, Vita Salute University Medical School, Via Stamira D'Ancona 20, 20127 Milan, Italy. cavallaro.roberto@hsr.it
The Journal of Clinical Psychiatry
|March 9, 2004
Summary
Low-dose cabergoline effectively treated risperidone-induced hyperprolactinemia in schizophrenia patients. This intervention normalized prolactin levels and resolved symptoms without side effects, improving patient management.
Area of Science:
- Endocrinology
- Psychiatry
- Pharmacology
Background:
- Dopamine D(2) blockers like risperidone frequently cause hyperprolactinemia.
- Hyperprolactinemia leads to endocrine and sexual side effects, impacting patient adherence.
- This study addresses the need for effective management of risperidone-induced hyperprolactinemia.
Purpose of the Study:
- To assess the efficacy and tolerability of low-dose cabergoline.
- To treat symptomatic hyperprolactinemia in patients on risperidone.
- To evaluate cabergoline's impact on prolactin levels and clinical symptoms.
Main Methods:
- Pilot study involving 19 schizophrenia patients treated with risperidone.
- Patients received low-dose cabergoline (0.125-0.250 mg/week) for 8 weeks.
- Plasma prolactin levels were measured at baseline and study end.
Main Results:
- Significant reduction in mean plasma prolactin levels observed (p <.05).
- Eleven patients achieved remission with normalized prolactin levels.
- No adverse effects or changes in patient psychopathology were reported.
Conclusions:
- Low-dose cabergoline appears safe and effective for treating risperidone-induced hyperprolactinemia.
- This approach may benefit a significant number of patients experiencing this side effect.
- Cabergoline offers a potential solution to improve treatment adherence in patients on risperidone.